Skip to main content

Table 4 Cost-effectiveness results

From: The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation

Discounted results (Results per 2,000,000 people) Current practice (CP) Policy 1a Policy 2b Policy 3c Policy 1 — CP Policy 2 — CP Policy 3 — CP
Life years (1,000) 19,515 19,580 19,564 19,601 65 49 86
QALYs (1,000) 12,006 12,103 12,082 12,188 97 76 182
Informal care (1,000) 4,975 4,947 4,953 4,898 −27 −22 −77
Days off sick (100) 1,733 1,705 1,711 1,673 −27 −21 −60
QALY loss due to depression (1,000) 1,746 1,695 1,702 1,631 −51 −44 −115
Costs (2013, £1,000,000) 29,626 30,676 34.475 36,431 1,050 4,849 6,805
Costs (2013 UK £1,000,000) Undiscounted
 Complications management 9,833 9,644 9,459 9,428 −190 −374 −405
 Annual review 9,134 9,222 9,200 9,294 88 66 161
 Primary care management 11,169 11,337 11,281 11,470 167 112 300
 Ongoing diabetes management (excluding above) 6,833 6,865 6,856 6,875 31 23 42
 Diagnostic interview 1,271 1,320 5,588 5,840 50 4,317 4,569
 Opportunistic screening 107 112 547 574 5 440 467
 Depression treatment 3,215 4,666 5,349 7,728 1,451 2,134 4,513
 Total cost 41,562 43,165 48,281 51,209 1,603 6,719 9,647
  1. CP Current practice, IHD Ischaemic heart disease, MI Myocardial infarction, CHF Congestive heart failure. aPolicy 1 = Collaborative care; bPolicy 2 = Opportunistic screening; cPolicy 3 = both collaborative care and opportunistic screening